Coronavirus Update: J&J’s Single Dose Stands Out From COVID Vaccine Crowd

Phase III Planned For September

J&J is a few months behind companies like Moderna, Pfizer and AstraZeneca in the race to develop a vaccine, but a safe and effective single dose immunization would be a game changer.

Manchester_Metro
Manchester, UK: restrictions on social gatherings were reintroduced in the city after rates of transmission began rising again • Source: Shutterstock

Johnson & Johnson has presented data showing its COVID-19 vaccine candidate provides protection for animals with a single dose, and has now progressed into Phase I/II human studies.

The data, published in Nature show its investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip